Deficit Super Committee Inaction May Be Best Scenario For Biopharma
Executive Summary
It may be a best-case scenario for the biopharmaceutical industry if the Joint Select Committee on Deficit Reduction is unable to produce a proposal by Thanksgiving to cut the federal deficit by at least $1.2 trillion over 10 years.
You may also be interested in...
"Medicare Exchange" Proposal From Healthcare Leadership Council Could Deter Threat Of Part B Drug Payment Reductions
Healthcare Leadership Council sends "super committee" recommendations, including Medicare reforms, that could save $410 billion in health care costs.
GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience
When Ralph Neas joins the Generic Pharmaceutical Association as CEO on Sept. 12 he will face many of the same challenges he’s had as CEO of the National Coalition on Health Care: energizing reform-minded partners to advocate for legislative and policy changes.
GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience
When Ralph Neas joins the Generic Pharmaceutical Association as CEO on Sept. 12 he will face many of the same challenges he’s had as CEO of the National Coalition on Health Care: energizing reform-minded partners to advocate for legislative and policy changes.